AQST vs. XERS, CHMA, SCPH, OPTN, CMRX, PRTA, ARQT, SAVA, GYRE, and INVA
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Xeris Biopharma (XERS), Chiasma (CHMA), scPharmaceuticals (SCPH), OptiNose (OPTN), Chimerix (CMRX), Prothena (PRTA), Arcutis Biotherapeutics (ARQT), Cassava Sciences (SAVA), Gyre Therapeutics (GYRE), and Innoviva (INVA). These companies are all part of the "medical" sector.
Xeris Biopharma (NASDAQ:XERS) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.
Xeris Biopharma currently has a consensus target price of $4.63, indicating a potential upside of 142.46%. Aquestive Therapeutics has a consensus target price of $8.00, indicating a potential upside of 160.59%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Xeris Biopharma.
Xeris Biopharma has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.95, suggesting that its stock price is 195% more volatile than the S&P 500.
Aquestive Therapeutics received 58 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 66.67% of users gave Aquestive Therapeutics an outperform vote.
42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by company insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Aquestive Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.33 beat Aquestive Therapeutics' score of 0.00 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.
Xeris Biopharma has a net margin of -37.58% compared to Xeris Biopharma's net margin of -55.85%. Xeris Biopharma's return on equity of 0.00% beat Aquestive Therapeutics' return on equity.
Aquestive Therapeutics has lower revenue, but higher earnings than Xeris Biopharma. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Aquestive Therapeutics beats Xeris Biopharma on 13 of the 19 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
